Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial
Primary result · % weight reduction from randomizationResult — go to the resultMean difference 3.1 % 95% CI 1.1–5.1Authors' conclusion
Stepping up early BT nonresponders to BT + AOM improves their 24-week weight loss.
Study context
- Population
- Adults with BMI ≥31 kg m-2 (≥28 kg m-2 with obesity-related comorbidity) who lost <2.0% of initial weight in a 4-week behavioral treatment (BT) run-in (early nonresponders)147 in run-in
- Participants
- 76 adults
- Comparison
- BT plus AOM vs BT plus placebo in early nonresponders to BT
- BT + AOMn = 38
- BT + Pn = 38reference
- Primary endpoint
- Weight loss (% reduction in weight) from randomization
- Follow-up
- Week 24
Methodological detailsdouble-blind, placebo-controlled, proof-of-principle
- Double-blind
- Placebo-controlled
- Proof-of-principle
Primary result
% weight reduction from randomization
Mean difference
3.1 %
95% CI 1.1–5.1
P = 0.003
Change by group
BT + AOM
5.9
mean · SE 0.7 · %
BT + P
2.8
mean · SE 0.7 · %
BT + AOMvs BT + P
mean difference 3.1 % (95% CI 1.1–5.1); P = 0.003
As reported in the abstract
Original publication
Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial. Nat Med. Published 7 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →